| Abstrakt: |
A recent study conducted in Milan, Italy, examined the effectiveness of a 2-year treatment with Dupilumab, a drug used to treat atopic dermatitis (AD), on the depressive and anxiety symptoms of patients with AD. The study found that after 2 years of treatment, patients experienced significant improvements in both their dermatological disease and comorbid depression/anxiety. However, 17.5% of patients still reported residual depressive symptoms, and 13% reported residual anxiety symptoms. The study identified several predictors of the persistence of these symptoms, including higher body mass index, lower impact of dermatological disease on quality of life, more severe depressive symptoms, and female gender. The researchers recommend that dermatologists closely monitor patients who are at a greater risk of maintaining residual psychiatric symptoms despite therapy. [Extracted from the article] |
